HOME >> BIOLOGY >> NEWS
Tumor response may not be best measure of efficacy in non-small cell lung cancer treatment

Researchers typically evaluate the effectiveness of a new cancer treatment by looking at how tumors respond to it. But in the case of advanced non-small cell lung cancer, there may be a better way to assess effectiveness.

A new Southwest Oncology Group study led by a team of UC Davis Cancer Center researchers suggests that an alternative measurement "disease control rate" may be a more powerful predictor of survival than tumor shrinkage. The research was presented today at the annual meeting of the American Society of Clinical Oncology in Atlanta.

"If validated, this 'early look' statistical measure could enhance efficacy assessment, with broad implications for the design of future cancer clinical trials for advanced non-small cell lung cancer," said Primo N. Lara, Jr., associate professor of hematology and oncology at UC Davis Cancer Center and lead author of the new study.

Lara and his colleagues defined the disease control rate as the percentage of patients who have a partial or complete response to an investigational treatment plus those whose disease stabilizes.

"In the past, we have used the complete response rate plus the partial response rate, or CR + PR, as our sole efficacy measure," Lara said. "The disease control rate, DCR, is the complete response rate plus the partial response rate plus the rate of patients with stabilized disease, or DCR = CR + PR + SD. This measure may better predict how a new drug will affect survival."

In their study, the investigators pooled data from 984 patients with advanced non-small cell lung cancer who participated in three randomized SWOG trials of platinum-based chemotherapy regimens.

Of the 886 patients who were alive two months after beginning treatment, 62 percent had stable disease, meaning their cancer had not progressed since entering the clinical trial. Another 19 percent had a complete or partial response, meaning their tumors had disappeared or reduced in size. Ad
'"/>

Contact: Claudia Morain
claudia.morain@ucdmc.ucdavis.edu
916-734-9023
University of California, Davis - Health System
5-Jun-2006


Page: 1 2

Related biology news :

1. Tumor painting revolutionizes fight against cancer
2. Tumor vessels identified by unique molecular markers
3. Tumors stopped from spreading to new sites
4. Chest Tumors -- Prevention, treatment and future perspectives
5. Tumor cells evade death through autophagy
6. Tumor-free breast tissue can have precancerous changes
7. Tumor-suppressor gene is critical for placenta development
8. Tumor cells that border normal tissue are told to leave
9. Tumor suppressor activity of PTEN
10. Tumor individuality useful for guiding rational chemotherapeutic decisions
11. MIT model could predict cells response to drugs

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/13/2017)... MONICA, Calif. , April 13, 2017 ... New York will feature emerging and evolving ... Summits. Both Innovation Summits will run alongside the expo ... of speaker sessions, panels and demonstrations focused on trending ... coast,s largest advanced design and manufacturing event will take ...
(Date:4/11/2017)... N.Y. , April 11, 2017 ... fingerprints, but researchers at the New York University ... College of Engineering have found that partial similarities ... security systems used in mobile phones and other ... thought. The vulnerability lies in the ...
(Date:4/5/2017)... Today HYPR Corp. , leading innovator ... of the HYPR platform is officially FIDO® Certified ... architecture that empowers biometric authentication across Fortune 500 enterprises ... over 15 million users across the financial services industry, ... product suites and physical access represent a growing portion ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... for two-dimensional representations of a complex biological network, a depiction of a system ... big mess,” said Dmitry Korkin, PhD, associate professor of computer science at Worcester ...
(Date:10/12/2017)... ... ... AMRI, a global contract research, development and manufacturing organization ... quality of life, will now be offering its impurity solutions as a stand-alone ... for all new drug products, including the finalization of ICH M7 earlier this ...
(Date:10/11/2017)... USA (PRWEB) , ... October 11, 2017 , ... ComplianceOnline’s ... take place on 7th and 8th June 2018 in San Francisco, CA. The Summit ... as well as several distinguished CEOs, board directors and government officials from around the ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... implantation and pregnancy rates in frozen and fresh in vitro fertilization (IVF) ... and maternal age to IVF success. , After comparing the results from the ...
Breaking Biology Technology:
Cached News: